- PreveCeutical moves on recent stock split to boost share appeal
- Company’s organic therapeutics aim to relieve maladies for patients with diabetes, brain injuries and other conditions
- Alternative medicines market expected to generate nearly $200 billion in revenues by 2025
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) continues working to shore up its share appeal while seeking remedies for a variety of physical ailments through its nature-centric research to help patients with type 2 diabetes and obesity, mild traumatic brain injury, cancer and pervasive pain.
PreveCeutical Medical completed a forward stock split last month on the basis of five new shares per one existing share, which resulted in a corresponding forward split of millions of common share purchase warrants issued following a non-brokered private placement last year (http://ibn.fm/MObzY). The 20.28 million (4.07 million pre-split) common share purchase warrants issued after the June 2017 financing measure allowed holders to buy into the company at a price of $1 per share during the 12 months after the warrants were issued. The expiry date is being extended by an additional 12 months to facilitate their conversion (http://ibn.fm/DPJWn).
The warrant extension will also allow holders to buy shares at a price of $0.20 per share until June 29, 2019. An exception clause allows the company to accelerate the expiration date for exercising the warrants, with 14 business days’ notice, if the closing price of the shares on the Canadian Securities Exchange is at least $0.30 or more for 10 consecutive business days.
“We believe the Stock Split demonstrates the Company’s continued commitment to broaden its shareholder base and we anticipate that the Stock Split will make PreveCeutical’s securities more accessible to investors and enhance liquidity for shareholders,” CEO, president and board chairman Stephen Van Deventer stated in a news release.
PreveCeutical is a company dedicated to providing medical patients with natural and nature-inspired formulations to treat select maladies and help prevent them from occurring. The company has five research and development programs under way and expects to partner with other companies to fund clinical trials once proof of concept has been sufficiently developed (http://ibn.fm/ptWCS).
One area of focus for PreveCeutical has been to make non-psychoactive cannabis product CBD bioavailable to patients through the best means possible, which means enabling it to reach the brain by circumventing the digestive system’s friable processes. Through PreveCeutical’s Sol-gel nasal delivery system, the medication would be able to reach the brain directly through the blood-brain barrier.
The company recently announced that it has signed a non-disclosure agreement with a leading drug delivery device manufacturer to work with the Sol-gels (http://ibn.fm/B2dAg) in preparation for a marketable solution. Earlier this month, PreveCeutical announced an agreement with Stadnyk & Partners to obtain strategic finance and marketing advisory services that will help the company achieve its business growth goals (http://ibn.fm/m9ijw).
PreveCeutical’s drive to develop its Nature Identical line of biopharmaceuticals positions it to take advantage of the mainstreaming of the complementary and alternative medicine market, a sector that’s expected to generate $196.87 billion in revenues by 2025, according to a report by Grand View Research, Inc. (http://ibn.fm/SId04). The market has been driven by the popularity of herbal dietary supplements and other wellness therapies like yoga and acupuncture, but the recent global clamor for legal cannabis-derived products has sparked an explosion in market expectations. Research analyst company Brightfield Group expects the CBD market to reach $1 billion early in the next decade (http://ibn.fm/j1efl). Women’s Marketing, which collaborated with Rodale on original consumer research into the modern “Health and Wellness” consumer mindset, labels wellness “the new black” that has become a status symbol among consumers. The company’s report argues that women in the United States alone invest $40 billion into alternative medicine (http://ibn.fm/k4YQq).
For more information, visit the company’s website at www.PreveCeutical.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
